Review 11 March 2024

Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer

Authors

  • Lama Abujamous ,
  • Abderrezzaq Soltani ,
  • Hamda Al-Thawadi ,
  • Abdelali Agouni
CC BY 4.0 Published: 11 March 2024 DOI: 10.17305/bb.2023.9757

Abstract

Advanced ovarian cancer is a malignancy that spreads beyond the ovaries to the pelvis, abdomen, lungs, or lymph nodes. Effective treatment options are available to improve survival rates in patients with advanced ovarian cancer. These include radiation, surgery, chemotherapy, immunotherapy, and targeted therapy. Drug resistance, however, remains a significant challenge in pharmacotherapeutic interventions, leading to reduced efficacy and unfavorable patient outcomes. Combination therapy, which involves using multiple drugs with different mechanisms of action at their optimal dose, is a promising approach to circumvent this challenge and it involves using multiple drugs with different mechanisms of action at their optimal dose. In recent years, nanotechnology has emerged as a valuable alternative for enhancing drug delivery precision and minimize toxicity. Nanoparticles can deliver drugs to specific cancer cells, resulting in higher drug concentrations at the tumor site, and reducing overall drug toxicity. Nanotechnology-based drug delivery systems have the potential to improve the therapeutic effects of anti-cancer drugs, reduce drug resistance, and improve outcomes for patients with advanced ovarian cancer. This literature review aims to examine the current understanding of combining poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy in treating advanced ovarian cancer and the potential impact of nanotechnology on drug delivery.

Keywords

Ovarian carcinomas combination therapy PARP inhibitors immune checkpoint inhibitors nanomedicine

Full text

Introduction

Ovarian cancer is a leading cause of mortality among women globally [1]. It is often referred to as a “silent killer” due to the nonspecific symptoms in its early stages [2]. Consequently, symptoms signaling a severe condition may not be recognized until the disease has progressed to an advanced stage. Typical symptoms include pelvic pain, bloating, stomach discomfort, and urinary problems [3]. The high mortality rates of ovarian cancer are indeed attributed to its late diagnosis, with 60% of women being diagnosed in advanced stages [4]. Treatment options include debulking surgery or cytoreduction, chemotherapy, and radiation therapy, while advanced therapeutic approaches, such as targeted therapy, immunotherapy, and hormone therapy are also being considered [1].

Clinical researchers are continually exploring novel strategies and effective trial designs to test anticancer drugs. Many of these novel strategies are underpinned by the shift toward molecularly targeted drug development. Creating effective clinical trials is more challenging than ever due to the constrained resources and the niche patient groups for whom precision-targeted drugs are appropriate [5]. The past decade has seen exponential advances in ovarian cancer treatment, with numerous new investigational combination drugs and drug approvals. Combinations designed to overcome resistance mechanisms have garnered special attention [6]. Determining the best treatment regimens, evaluating new agents effectively, and improving patient outcomes remain elusive.

The development of nanomaterials has paved the way for a new frontier in cancer treatment with promising research in drug delivery systems [7]. Nanoparticles could potentially offer superior antineoplastic benefits compared to standard anticancer drugs, due to ease of manufacture, high efficacy, low toxicity, and aggressive tumor-targeting capabilities. These drug delivery systems include delivery carriers of anticancer drugs and target molecules [8].

This review focuses on two main areas: the combined and repurposed use of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) and immune checkpoint inhibitors (ICIs) in ovarian cancer, as well as the potential of nanomedicine as a novel approach to drug delivery. While existing literature addresses targeted therapy for ovarian cancer, there is no study that provides an in-depth analysis of personalized drug delivery methods specific to ovarian cancer.

Human ovarian cancer

Ovarian cancer is a prevalent malignancy with a high mortality rate, ranking as the world’s seventh most common malignant tumor and one of the most prevalent gynecologic cancer types [9]. Its mortality rate stands third behind cervical and uterine cancers [10]. Postmenopausal women, especially those over 65 years old, are at a higher risk [11]. The incidence of ovarian cancer has been rising with the mortality rate surging by 20.1% annually per 100,000 individuals in the Middle East and North Africa (MENA) region since 1990 [12]. Within the Gulf region, Bahrain has the highest age-standardized rate (ASR) per 100,000 women, followed by Qatar, Kuwait, Oman, the United Arab Emirates, and Saudi Arabia [13]. The incidence rate of ovarian cancer is highest in non-Hispanic white women, followed by Hispanic women, non-Hispanic black women, and Asian/Pacific Islander women [14].

The pathogenesis of ovarian cancer is linked to various risk factors, including regional epidemiological variations [10], genetic predispositions like hereditary breast and ovarian cancer (HBOC) syndrome, Lynch syndrome [15], advanced age at menopause, and hormone replacement therapy treatment [10]. Reproductive and hormonal factors, such as parity, contraceptive use, and breastfeeding, may reduce the risk of ovarian cancer. The relationship between risk factors and histotype varies due to etiological variations. For instance, patients with endometriosis are at a higher risk of developing mucinous ovarian cancer and clear cell ovarian cancer. Conversely, patients who undergo tubal ligation are at a reduced risk [16]. The association with other gynecological diseases and procedures, such as hysterectomy, pelvic inflammatory disease, polycystic ovarian syndrome, and ovarian cancer risk is less well defined [16]. Environmental and lifestyle factors, such as asbestos and talc powder exposure and cigarette smoking are also potential risk factors. What is certain is that further research is required to improve our understanding of the disease etiology and develop more effective prevention and early detection strategies [16].

The pathophysiology of ovarian cancer is complex, impacting different cell types in the ovaries, including non-epithelial cells, such as germ cells and specialized gonadal stromal cells, as well as epithelial cells [17]. Over 90% of diagnosed cases of ovarian cancer are carcinomas, which are ovarian tumors with epithelial differentiation, accounting for the majority of ovarian cancer-related deaths [17].

Pathologists divide epithelial ovarian carcinomas (EOCs) into five main types based on their microscopic appearance: high-grade serous carcinomas (HGSCs), endometrioid carcinoma (EC), clear cell carcinoma (CCC), low-grade serous carcinomas (LGSCs), and mucinous carcinoma (MC) [15, 17]. These different subtypes of EOCs have distinct clinical and molecular characteristics that impact the diagnosis, prognosis, and treatment strategy. HGSC is the most common and aggressive EOC subtype, typically chemoresistant, and commonly affects postmenopausal women [18].

Ovarian carcinomas can also be classified into two tumor types, I and II, based on their distinct characteristics [17]. Type I tumors are low-grade, non-aggressive, and genetically stable, often arising from benign tumors or endometriosis [19]. Common somatic mutations in Type I tumors impair cell signaling pathways or chromatin folding complexes, including B-Raf Proto-Oncogene (BRAF), Kirsten ras oncogene homolog (KRAS), or phosphatase and tensin homolog (PTEN) mutations found in ECs, CCCs, MCs, and LGSCs. Conversely, type II tumors are high-grade, physiologically aggressive, and prone to spreading from small lesions. HGSCs, the most common type II tumors, feature tumor protein 53 (TP53) mutations and multiple gene modifications (e.g., breast cancer gene or BRCA1/2), which lead to homologous recombination (HR) anomalies [15, 18, 20].

To evaluate ovarian cancer specimens, pathologists must report the histology, tumor grade, particularly for serous malignancies, and tumor stage, which refers to the degree of systemic involvement in other tissues/organs, according to the College of American Pathologists standard [21]. Prognostic predictions in ovarian cancer are challenging due to the diverse range of tumors. The standard treatment for advanced ovarian cancer involves primary cytoreductive surgery, followed by platinum-based chemotherapy. The aim of cytoreductive surgery is to establish an accurate diagnosis, remove disease-bearing tissue with poor perfusion, and reduce tumor size to improve the effectiveness of adjuvant treatment. Combination treatment with surgery and chemotherapy is the conventional approach to manage ovarian cancer [22, 23].

Current treatment of ovarian cancer

The first-line treatment of ovarian carcinoma involves optimal debulking surgery followed by platinum/gemcitabine and taxane-based chemotherapy [24]. Despite the high response rate, recurrence is common within three years. In platinum-resistant cases (with relapse occurring within six months of treatment) or in platinum-refractory disease (progressing within four weeks following platinum-based chemotherapy), approximately 20%–25% of patients have a poor prognosis when they first relapse [25]. Single non-platinum agents like paclitaxel and pegylated liposomal doxorubicin (PLD) are often prescribed in platinum-resistant diseases with limited efficacy and poor outcomes. Given the diverse nature of clinical presentations of ovarian carcinomas, both at diagnosis and upon recurrence, it is imperative to devise better approaches to predict both immediate and long-term treatment outcomes for both newly diagnosed and recurrent cases [23].

Given the considerable risk of drug resistance following initial therapy with first-line treatment, it is paramount to consider a broader array of treatment strategies for upfront and recurrent settings to improve patient outcomes [23]. Targeted therapy is a promising approach to address tumor cell alterations that promote their growth, proliferation, and metastasis. Potential therapeutic targets in gynecological malignancies include tumor-intrinsic signaling pathways, angiogenesis, HR deficiency (HRD), hormone receptors, and immunologic factors [26]. Targeted therapy includes signaling pathway inhibitors, selective estrogen receptor down-regulators, anti-angiogenic agents, PARPis, and ICIs.

The U.S. Food and Drug Administration (FDA) has recently approved bevacizumab, pembrolizumab, and olaparib to treat recurrent metastatic or high-risk gynecological malignancies in selected patients [24]. Clinical applications of targeted drugs and other potential treatments are still being extensively investigated to develop better and more personalized treatment strategies for patients with ovarian carcinomas.

There are numerous factors that impact the selection of therapy for ovarian cancer. These include treatment indications, FDA approval, sensitivity to platinum-based therapies, outcomes of molecular studies, and testing strategies. Other important considerations include risk stratification, assessing the patient’s likelihood to respond to PARPis, and evaluating the efficacy of past treatments. Patient-specific factors like performance status, end-organ function, previous treatment side effects, toxicity profiles, patient adherence, and treatment costs should also be considered for a more holistic and patient-centered approach [27].

Surgery and chemoradiotherapy remain the gold standard therapy for ovarian cancer. The severe side effects associated with chemotherapy and radiation however underscore the need to explore alternative treatment strategies. Our enhanced understanding of ovarian cancer biology has paved the way for molecular targeted therapies which could potentially offer better patient outcomes. The pharmacotherapies currently available for the treatment of ovarian cancer and their drawbacks are summarized in Table 1.

Table 1 Currently available therapeutic options for ovarian cancer treatment
Drug Class Target Major drawbacks Database
Thiotepa Organic thiophosphoric acids DNA Nausea, vomiting, loss of appetite, stomach pain, unusual tiredness or weakness, dizziness, headache, blurry vision, sore or red eyes, hair loss, risk for other cancers NCI, Drug bank, MedlinePlus
Paclitaxel Taxanes Tubulin beta-1 chain, Apoptosis regulator Bcl-2, Microtubules Myelosuppression, peripheral neuropathy, alopecia, hypersensitivity reactions NCI, UTD, Drug bank
Doxorubicin Anthracyclines DNA, DNA topisomerase 2-alpha/2-beta Risk of secondary malignancies, premature menopause NCI, UTD, Drug bank
Topotecan Camptothecin DNA, DNA topoisomerase 1 Bone marrow suppression NCI, UTD, Drug bank
Nivolumab Immune checkpoint inhibitor PD-1 Toxicity, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and skin reactions – May cause immune-mediated complications UTD, Drug bank, Not included in the FDA-approved list by NCI for ovarian cancer
Pembrolizumab Immune checkpoint inhibitor PD-1 Toxicity, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and skin reactions – May cause immune-mediated complications Drug bank, Not included in the FDA-approved list by NCI for ovarian cancer
Atezolizumab Immune checkpoint inhibitor PD-L1 Toxicity, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and skin reactions – May cause immune-mediated complications Drug bank, Not included in the FDA-approved list by NCI for ovarian cancer
Mirvetuximab soravtansine Monoclonal antibody (mAb) Folate receptor alpha Ocular toxicity, pneumonitis, peripheral neuropathy NCI, UTD, Drug bank
Cyclophosphamide Nitrogen mustard DNA Neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, diarrhea. NCI, UTD, Drug bank
Olaparib PARP inhibitor PARP1, PARP2, PARP3 MDS/AML, cardiovascular toxicity NCI, UTD, Drug bank
Niraparib PARP inhibitor PARP1, PARP2, PARP3 MDS/AML, thrombocytopenia, anemia, neutropenia NCI, UTD, Drug bank
Rucaparib PARP inhibitor PARP1, PARP2, PARP3 MDS/AML, gastrointestinal toxicity NCI, UTD, Drug bank
Melphalan Phenylalanine DNA Vomiting, ulceration of the mouth, diarrhea, hemorrhage of the gastrointestinal tract NCI, Drug bank
Carboplatin Platinum compounds DNA Neutropenia, hepatotoxicity NCI, UTD, Drug bank
Cisplatin Platinum compounds DNA Nephrotoxicity, hearing problems NCI, UTD, Drug bank, MedlinePlus
Gemcitabine Pyrimidine 2’-deoxyribonucleosides DNA, Ribonucleoside-diphosphate reductase Myelosuppression, paresthesia, severe rash NCI, UTD, Drug bank
Docetaxel Taxane Microtubules Myelosuppression, peripheral neuropathy, alopecia, hypersensitivity reactions UTD, Drug bank, Not included in the FDA approved list by NCI for ovarian cancer
Pazopanib VEGF inhibitor VEGFR-1, VEGFR-2, VEGFR-3 Cardiovascular toxicity, hepatic toxicity, hypertension, gastrointestinal toxicity UTD, Drug bank, Not included in the FDA-approved list by NCI for ovarian cancer
Bevacizumab VEGF inhibitor VEGF-A Cardiovascular toxicity, gastrointestinal perforation, arterial thromboembolic events, hypertension NCI, UTD, Drug bank

NCI: National Cancer Institute; UTD: Up-to-Date (an evidence-based medicine website); VEGF: Vascular endothelial growth factor; VEGFR: VEGF receptor; PD-1: Programmed death protein 1; FDA: Food and Drug Administration; PD-L1: Programmed death-ligand 1; PARP: Poly (ADP-ribose) polymerase; MDS/AML: Myelodysplastic syndrome/acute myeloid leukemia.

PARP inhibitors (PARPis) in the treatment of ovarian cancer: Current status and future directions

In recent years, there has been a marked increase in research focus on improving the efficacy of existing treatments for advanced ovarian cancer. While platinum-based chemotherapy remains the treatment mainstay for advanced ovarian cancer, most patients develop resistance and experience relapse within the first two years of treatment [28]. This pressing challenge justifies the quest of the research community to explore and develop innovative approaches to manage advanced ovarian cancer.

One of the most promising treatment strategies for advanced ovarian cancer involves the use of PARPis. These inhibitors target DNA repair and are primarily active in cells with defective DNA repair via the HR pathway. HRD is evident in cells with mutant germline BRCA function and in a high percentage of non-BRCA-mutated ovarian cancers [29]. BRCA mutations are found in nearly 15% of all EOCs and up to 22.6% of HGSOCs, with somatic BRCA mutations identified in approximately 7% of high-grade serous EOCs [30]. PARPis have demonstrated efficacy beyond germline BRCA mutations in DDR deficiency. Other somatic mutations in genes, such as Ataxia telangiectasia and Rad3-related protein (ATR), Checkpoint kinase 1/2 (CHK1/2), BRCA1-associated RING domain protein 1 (BARD1), BRCA1-interacting protein 1 (BRIP1), Deleted in split hand/split foot 1 (DSS1), Nijmegen breakage syndrome 1 mutated gene (NBS1), Partner and Localizer of Breast Cancer 2 (PALB2), RAD51 recombinase (RAD51), cyclin-dependent kinase 12 (CDK12), Ataxia-Telangiesctasia Mutated (ATM), Fanconi anemia complementation group, Partner and Localizer of BRCA2 (PALB2), X-Ray Repair Cross Complementing 2 (XRCC2), X-ray repair cross-complementing group 3 (XRCC3), TP53, or PTEN may serve as diagnostic biomarkers for PARPis treatment in various cancers without BRCA mutations [6].

Moreover, PARPis result in synthetic lethality, which is the simultaneous perturbation of two genes that leads to cellular or organismal death [31]. Synthetic lethality may be one of the most promising pathways in the realm of personalized medicine which exploits dysregulated DNA damage. PARP1 undergoes poly (ADP) ribosylation because of its affinity to DNA strand breaks. The process initiates the recruitment of additional DNA repair pathways as well as poly (ADP) ribosylation [32]. When PARP1 is inhibited, single-strand breaks (SSB) lesion repair fails, while double-strand breaks (DSB) repair remains unaffected. Because PARP1 enzymatic activity is reduced in BRCA1/2-deficient cells, SSBs are transformed into DSBs and are repaired by HR, resulting in cell cycle arrest and death [6].

PARPis have been shown to improve progression-free survival and overall survival in patients with platinum-sensitive recurrent ovarian cancer and subsequent high-grade ovarian cancer which did not progress following first-line platinum-based chemotherapy [6]. Anti-angiogenic therapy and PARPis have recently been added to standard treatment protocols. Several studies have demonstrated that such combinations improve progression-free survival and overall survival in women with ovarian cancer [33]. However, further research is needed to determine the most suitable patient candidates who will benefit the most from these treatment approaches. Notably, the impact of PARPis on immune cells may amplify the anticancer activity of ICIs, as dying tumor cells can trigger an immune response that is mediated in part by various transcriptional factors and chemokines [1, 7]. Anticancer drugs inhibiting the immune checkpoint could be boosted if the immune system responds to dying tumor cells [34]. One crucial aspect that is still under investigation is to discern which patients benefit the most from combination therapy with PARPis and ICIs [1]. In summary, PARPis offer a promising therapeutic approach for patients with advanced ovarian cancer, especially those with HRD. Combination therapy with ICIs could prove to be a viable treatment option to further improve patient outcomes.

Figure 1.
Figure 1. Interaction between PARPis and ICIs. When double-strand DNA breaks (DSBs) occur, DNA fragments accumulate in the cytoplasm, and the PARP complex is blocked by PARPis. This results in the collection of neo-antigens on the cell surface, which are recognized by antigen-presenting cells (APCs), triggering an immunological response. The cytosolic sensor cGMP-AMP synthetase (cGAS) identifies fragments of DNA, activating cyclic GMP-AMP (cGAMP), which then activates the STING pathway. The STING pathway modulates transcription factors like nuclear factor-κB (NF-κB) and interferon regulatory factor 3 (IRF3), leading to the transcription of cytokines, including interferon (IFN), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α). IFN increases the expression levels of programmed cell death ligand 1 (PD-L1). DSBs activate the ataxia-telangiectasia mutated (ATM)-(ATR) serine/threonine kinase (ATR)-checkpoint kinase 1 (CHEK1) and signal transducers and activators of transcription (STAT)-IRF sensor pathways, leading to enhanced PD-L1 expression. DSBs also inhibit glycogen synthase kinase 3β (GSK-3β), which is involved in PD-L1 proteasomal degradation, resulting in increased PD-L1 cellular expression. PARPis: Poly (ADP-ribose) polymerase (PARP) inhibitors; ICIs: Immune checkpoint inhibitors; PARP: Poly (ADP-ribose) polymerase; TIL: Tumor-infiltrating lymphocytes; TMB: Tumor mutation burden.

Immunotherapy with immune checkpoint inhibitors (ICIs) in ovarian cancer

Immunotherapy has revolutionized cancer therapy with ICIs playing a central and promising role in combating various malignancies. These anticancer agents are designed to block mechanisms that inhibit the immune response [34] by targeting programmed death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [35]. Among gynecologic cancers, endometrial cancer is most responsive to ICIs, while ovarian, cervical, and vulvar cancer are significantly less so [36]. Combination therapy of ICIs and other anticancer agents, including PARPis, has shown promise in treating ovarian, cervical, and vulvar cancer as reflected in findings of several phases I and II clinical trials [37]. ICIs, whether administered alone or in combination with other therapies, have been shown to prolong the survival of patients with advanced diseases, such as melanoma, genitourinary, lung, and gastric cancer. However, the efficacy of ICIs varies depending on the cancer type and even within the same tumor tissue cohort. Notably, the benefits of ICIs therapy may be limited in some common tumor types, such as prostate and breast cancer [37].

In conclusion, the long-term use of ICIs as a single therapy is marked with limited efficacy. Combination therapies, particularly with PARPis, may help in overcoming resistance and augmenting the beneficial effects of ICIs [38].

Combining PARPis and ICIs in ovarian cancer treatment

PARPis or ICIs monotherapy often leads to resistance, necessitating combination therapies to bypass resistance and enhance efficacy [37]. PARPis affect the tumor immune microenvironment through molecular and cellular mechanisms, making them a compelling candidate for combination with ICIs. PARPis have been linked to increased PD-L1 expression, potentially mediated by the inactivation of glycogen synthase kinase (GSK)-3β, leading to decreased PD-L1 degradation by proteasomes and increased surface expression [38, 39]. Additionally, PARPis activate the STING pathway to promote PD-L1 expression in response to interferon release and upregulate PD-L1 through the ATM-ATR-CHEK1 pathway [38] (Figure 1).

Research has shown that cancer cells increase the production of PD-L1 in response to DNA damage caused by PARPis, which inhibits T-cell response and may reduce treatment efficacy [6, 37]. This suggests a potential role for PARPis in treating platinum-resistant cancers by counteracting the effects of PD-L1. Furthermore, the immunomodulatory effect of PARPis justifies their combination with ICIs, as this synergy has shown great promise in advanced ovarian cancer treatment [37, 38].

To date, four clinical trials (TOPACIO/Keynote162/NCT02657889, NCT02484404, MEDIOLA/NCT02734004, and NCT03574779) investigating the efficacy of combining PARPis with ICIs have provided insights into the potential benefits of the combination approach been published, including [38]. Unlike BRCA inhibitors monotherapy, which proved more effective in patients with BRCA mutations, these studies showed there was no significant difference in response or survival rates based on BRCA or HR status in the combination therapy [37]. This suggests that the importance of BRCA mutations may be diminished in the context of PARP and ICI combination therapy, paving the possibility open for further investigation in future trials [37, 38].

In conclusion, the combination therapy improves anti-tumor immune response and boosts the efficacy of PARPis in ovarian cancer. Clinical trials in women with ovarian cancer have shown promising results by displaying higher response rates and progression-free survival.

Challenges in drug delivery for combining PARPis and ICIs

Advances in our understanding of cancer microenvironments and intracellular signaling pathways have paved the way to develop targeted molecular therapies for ovarian cancer. These therapies can attack tumor cells or their microenvironment by targeting molecules that induce cell death or promote cell survival [5]. Traditional chemotherapy using cytotoxic drugs, targeted molecular inhibitors, and immunotherapy can fail when ovarian cancer cells acquire resistance, metastasize, or when patients no longer tolerate the treatment due to severe side effects.

To surmount these challenges, targeted delivery systems like antibody-drug conjugates (ADCs), peptide/folate/aptamer-drug conjugates, polymer-drug conjugates, ligand-functionalized nanomedicines, and dual-targeted nanomedicines have come to the fore over the past decade [24]. These delivery systems have the potential to improve the efficacy of ovarian cancer chemotherapy and molecular therapy in both preclinical and clinical settings by enhancing therapeutic agent selectivity, overcoming drug resistance, and minimizing systemic toxicity.

Specifically, nanoconjugates, branching dendrimers, liposomes, nanostructured lipid formulations, and polymer nanomicelles, in particular, are nanocarriers that have been developed extensively to deliver drugs to cancer cells [40]. These biopharmaceutical delivery systems offer several advantages, including enhanced drug biodegradability, increased therapeutic impact, biocompatibility, non-toxic and non-inflammatory properties, and potential for scalable manufacturing [41]. In the context of chemotherapeutic systems, it is crucial that nanoformulations have a high drug-loading capacity, the ability to dissolve pharmaceuticals in the inner core, and the capability to preferentially accumulate in tumor tissue via passive or active targeting mechanisms [13].

Conclusion and future perspectives

Treating ovarian cancer remains a significant clinical challenge due to the persistent issue of chemoresistance and the lack of additional treatment options to overcome it effectively. The biological mechanisms underlying drug resistance remain poorly understood. Identifying genes associated with chemotherapy response and patient survival may provide valuable insights to guide prognosis and treatment decisions and prevent chemoresistance. Unlike most malignancies, ovarian cancer has limited therapy options, making it paramount to gain a deeper understanding of the molecular pathways involved in drug resistance to develop targeted interventions that combat or eliminate resistance.

In a recent study by Giannini et al., significant concerns pertaining to the utilization of PARPis have been thoughtfully addressed. A notable concern highlighted is the reoccurrence of the disease in a significant number of individuals who received treatment with these inhibitors within a 30-month span after their first diagnosis [42]. There are lingering uncertainties surrounding the management of relapses, the optimal positioning of PARPis as either first-line or second-line therapies, and whether patients can be managed effectively with PARPis alone. To address these concerns, current clinical studies are actively exploring diverse strategies, such as the integration of PARPis with chemotherapy, antiangiogenic therapy, ICIs, or other therapeutic interventions that modulate the DNA damage response. It is noteworthy that the initial results derived from these trials indicate that the combination of PARPis with chemotherapy may not yield substantial improvements in patient outcomes. On the other hand, the potential of PARPis in conjunction with antiangiogenic therapy is encouraging, as is the prospect of utilizing PARPis to augment the effectiveness of ICIs. In addition, scholars are currently engaged in the investigation of methodologies aimed at addressing resistance to PARPis by targeting the cell cycle [42].

Advances in technology and analytical tools have provided researchers with a more nuanced understanding of ovarian tumors. They are now able to identify specific biomarkers crucial for predicting tumor response to targeted therapy. Overcoming drug resistance is indeed a significant challenge that could potentially be overcome by promising combination treatments that inhibit multiple targets but this approach warrants further investigation. Moreover, targeted drug delivery via nanoparticles has shown significant therapeutic potential to improve cancer treatment efficacy compared to traditional chemotherapy. Nanoparticules-based drug delivery systems, such as nanocarriers, hold immense promise as a primary treatment option for ovarian cancer and could also play a pivotal role in managing other types of cancer in the future.

References

  1. Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, et al. Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med 2019;8(16):7018–31. https://doi.org/10.1002/cam4.2560
  2. Gupta P, Miller A, Olayanju A, Madhuri TK, Velliou E. A systematic comparative assessment of the response of ovarian cancer cells to the chemotherapeutic cisplatin in 3D models of various structural and biochemical configurations—does one model type fit all?. Cancers 2022;14(5):1274. https://doi.org/10.3390/cancers14051274
  3. Dilley J, Burnell M, Gentry-Maharaj A, Ryan A, Neophytou C, Apostolidou S, et al. Ovarian cancer symptoms, routes to diagnosis and survival—population cohort study in the ‘no screen’arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol 2020;158(2):316–22. https://doi.org/10.1016/j.ygyno.2020.05.002
  4. Noone A, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975–2015. Bethesda, MD: National Cancer Institute; 2018.
  5. Lee JM, Minasian L, Kohn EC. New strategies in ovarian cancer treatment. Cancer 2019;125:4623–9. https://doi.org/10.1002/cncr.32544
  6. Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, et al. The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol 2021;15:1179554921996288. https://doi.org/10.1177/1179554921996288
  7. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci 2020;7:193. https://doi.org/10.3389/fmolb.2020.00193
  8. Liu G, Yang L, Chen G, Xu F, Yang F, Yu H, et al. A review on drug delivery system for tumor therapy. Front Pharmacol 2021;12:735446. https://doi.org/10.3389/fphar.2021.735446
  9. Zhang Y, Luo G, Li M, Guo P, Xiao Y, Ji H, et al. Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis. BMC Cancer 2019;19(1):1–14. https://doi.org/10.1186/s12885-019-6139-6
  10. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Women’s Health 2019:287–99. https://doi.org/10.2147/IJWH.S197604
  11. Mohammadian M, Ghafari M, Khosravi B, Salehiniya H, Aryaie M, Bakeshei FA, et al. Variations in the incidence and mortality of ovarian cancer and their relationship with the human development index in European countries in 2012. Biomed Res Therapy 2017;4(08):1541–57. https://doi.org/10.15419/bmrat.v4i08.228
  12. Lawry J. Ovarian cancer: a patient centric approach. Middle East Medical Portal. 2018 [cited 2023 Sep 02].. Available from: https://www.middleeastmedicalportal.com/ovarian-cancer-a-patient-centric-approach/.
  13. Yan L, Shen J, Wang J, Yang X, Dong S, Lu S. Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose-Response 2020;18(3):1559325820936161. https://doi.org/10.1177/1559325820936161
  14. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018;68(4):284–96. https://doi.org/10.3322/caac.21456
  15. Helder-Woolderink JM, Blok E, Vasen HF, Hollema H, Mourits M, De Bock G. Ovarian cancer in Lynch syndrome: a systematic review. Eur J Cancer 2016;55:65–73. https://doi.org/10.1016/j.ejca.2015.12.005
  16. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017;14(1):9. https://doi.org/10.20892/j.issn.2095-3941.2016.0084
  17. Hatano Y, Hatano K, Tamada M, Morishige K-i, Tomita H, Yanai H, et al. A comprehensive review of ovarian serous carcinoma. Adv Anat Pathol 2019;26(5):329. https://doi.org/10.1097/PAP.0000000000000243
  18. Lisio M-A, Fu L, Goyeneche A, Gao Z-h, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci 2019;20(4):952. https://doi.org/10.3390/ijms20040952
  19. Watanabe T, Nanamiya H, Endo Y, Kojima M, Nomura S, Furukawa S, et al. Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer. J Ovar Res 2021;14:1–9. https://doi.org/10.1186/s13048-021-00876-z
  20. Bodelon C, Killian JK, Sampson JN, Anderson WF, Matsuno R, Brinton LA, et al. Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity. Clin Cancer Res 2019;25(19):5937–46. https://doi.org/10.1158/1078-0432.CCR-18-3720
  21. Movahedi-Lankarani S, Baker PM, Gilks B, Soslow RA, Otis CN, Oliva E. Protocol for the examination of specimens from patients with carcinoma of the ovary. Northfield, IL: College of American Pathologists. 2012.
  22. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin 2019;69(4):280–304. https://doi.org/10.3322/caac.21559
  23. Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer 2019;11. https://doi.org/10.1177/1179299X19860815
  24. Wang Q, Peng H, Qi X, Wu M, Zhao X. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther 2020;5(1):137. https://doi.org/10.1038/s41392-020-0199-6
  25. Christie E, Bowtell D. Acquired chemotherapy resistance in ovarian cancer. Ann Oncol 2017;28:VIII13–VIII15. https://doi.org/10.1093/annonc/mdx446
  26. Keyvani V, Riahi E, Yousefi M, Esmaeili S-A, Shafabakhsh R, Moradi Hasan-Abad A, et al. Gynecologic cancer, cancer stem cells, and possible targeted therapies. Front Pharmacol 2022;13:823572. https://doi.org/10.3389/fphar.2022.823572
  27. Anderson RK.. Clinical insights into advancements in epithelial ovarian cancer treatment: pharmacy times oncology edition 2023 [cited 2023 Sep 2]. Available from: https://www.pharmacytimes.com/view/clinical-insights-into-advancements-in-epithelial-ovarian-cancer-treatment.
  28. Hu Q, Kang W, Wu Q, Wang X, Wang Q, Luo T. Role of maintenance strategies in advanced epithelial ovarian cancer: a systematic review, network meta-analysis and cost-effectiveness analysis protocol. BMJ Open 2021;11(12):e051037. https://doi.org/10.1136/bmjopen-2021-051037
  29. Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer 2020;30(7). https://doi.org/10.1136/ijgc-2020-001288
  30. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 2015;5(11):1137–54. https://doi.org/10.1158/2159-8290.CD-15-0714
  31. Chandrasekaran A, Elias KM. Synthetic lethality in ovarian cancer. Mol Cancer Ther 2021;20(11):2117–28. https://doi.org/10.1158/1535-7163.MCT-21-0500
  32. Giordo R, Wehbe Z, Paliogiannis P, Eid AH, Mangoni AA, Pintus G, et al. Nano-targeting vascular remodeling in cancer: recent developments and future directions. Semin Cancer Biol 2022. https://doi.org/10.1016/j.semcancer.2022.03.001
  33. Garrido MP, Fredes AN, Lobos-González L, Valenzuela-Valderrama M, Vera DB, Romero C. Current treatments and new possible complementary therapies for epithelial ovarian cancer. Biomedicines 2021;10(1):77. https://doi.org/10.3390/biomedicines10010077.
  34. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 2020;11(1):3801. https://doi.org/10.1038/s41467-020-17670-y
  35. Zhu J, Yan L, Wang Q. Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis. J Ovar Res 2021;14(1):1–8. https://doi.org/10.1186/s13048-021-00862-5
  36. Pirš B, Škof E, Smrkolj V, Smrkolj Š. Overview of immune checkpoint inhibitors in gynecological cancer treatment. Cancers 2022;14(3):631. https://doi.org/10.3390/cancers14030631
  37. Wanderley CWS, Correa TS, Scaranti M, Cunha FQ, Barroso-Sousa R. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications. Front Immunol 2022;13:816642. https://doi.org/10.3389/fimmu.2022.816642
  38. Maiorano BA, Lorusso D, Maiorano MFP, Ciardiello D, Parrella P, Petracca A, et al. The interplay between PARP inhibitors and immunotherapy in ovarian cancer: the rationale behind a new combination therapy. Int J Mol Sci 2022;23(7):3871. https://doi.org/10.3390/ijms23073871
  39. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M-K, Hsu J-M, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017;23(14):3711–20. https://doi.org/10.1158/1078-0432.CCR-16-3215
  40. Santhosh S, Nanjan M, Chandrasekar M. Ovarian solid tumors: current treatment and recent developments using stimuli-responsive polymers: a systemic review. J Drug Deliv Sci Technol 2019;51:621–8. https://doi.org/10.1016/j.jddst.2019.03.018
  41. Yin W, Qian S-M. CD44v6-O-MWNTS-loaded gemcitabine and CXCR4 siRNA improves the anti-tumor effectiveness of ovarian cancer. Front Cell Develop Biol 2021;9:687322. https://doi.org/10.3389/fcell.2021.687322
  42. Giannini A, Di Dio C, Di Donato V, D’Oria O, Salerno MG, Capalbo G, et al. PARP inhibitors in newly diagnosed and recurrent ovarian cancer. Am J Clin Oncol 2023;46(9):414–9. https://doi.org/10.1097/COC.0000000000001024

About this article

Correspondence

*Correspondence to Abdelali Agouni: [email protected]

Article history

Received: 2023-09-02 · Accepted: 2023-11-23 · Rev-recd: 2023-09-25

Acknowledgements

The figure in this review was created using BioRender.com tools.

Conflicts of interest

Conflicts of interest: Authors declare no conflicts of interest.

Funding

Funding: This work was supported by Qatar University Internal Grant No. QUCG-CPH-22/23-535 to A. Agouni. The statements made herein are solely the responsibility of the authors. L.A. is supported by a Ph.D. graduate assistantship from the Office of Graduate Studies (Qatar University). The publication of this article was funded by the Qatar National Library.

Copyright

© 2023 Abujamous et al.

Downloads

Download data is not yet available.

References

Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, et al. Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med. 2019;8(16):7018-31. doi:10.1002/cam4.2560 DOI: https://doi.org/10.1002/cam4.2560

Gupta P, Miller A, Olayanju A, Madhuri TK, Velliou E. A systematic comparative assessment of the response of ovarian cancer cells to the chemotherapeutic cisplatin in 3D models of various structural and biochemical configurations—does one model type fit all?. Cancers. 2022;14(5):1274. doi:10.3390/cancers14051274 DOI: https://doi.org/10.3390/cancers14051274

Dilley J, Burnell M, Gentry-Maharaj A, Ryan A, Neophytou C, Apostolidou S, et al. Ovarian cancer symptoms, routes to diagnosis and survival—population cohort study in the ‘no screen’arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. 2020;158(2):316-22. doi:10.1016/j.ygyno.2020.05.002 DOI: https://doi.org/10.1016/j.ygyno.2020.05.002

Noone A, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975–2015. Bethesda, MD: National Cancer Institute;. 2018.

Lee JM, Minasian L, Kohn EC. New strategies in ovarian cancer treatment. Cancer. 2019;125:4623-9. doi:10.1002/cncr.32544 DOI: https://doi.org/10.1002/cncr.32544

Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, et al. The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol. 2021;15:1179554921996288. doi:10.1177/1179554921996288 DOI: https://doi.org/10.1177/1179554921996288

Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:193. doi:10.3389/fmolb.2020.00193 DOI: https://doi.org/10.3389/fmolb.2020.00193

Liu G, Yang L, Chen G, Xu F, Yang F, Yu H, et al. A review on drug delivery system for tumor therapy. Front Pharmacol. 2021;12:735446. doi:10.3389/fphar.2021.735446 DOI: https://doi.org/10.3389/fphar.2021.735446

Zhang Y, Luo G, Li M, Guo P, Xiao Y, Ji H, et al. Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis. BMC Cancer. 2019;19(1):1-14. doi:10.1186/s12885-019-6139-6 DOI: https://doi.org/10.1186/s12885-019-6139-6

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Women’s Health. 2019:287-99. doi:10.2147/IJWH.S197604 DOI: https://doi.org/10.2147/IJWH.S197604

Mohammadian M, Ghafari M, Khosravi B, Salehiniya H, Aryaie M, Bakeshei FA, et al. Variations in the incidence and mortality of ovarian cancer and their relationship with the human development index in European countries in 2012. Biomed Res Therapy. 2017;4(08):1541-57. doi:10.15419/bmrat.v4i08.228 DOI: https://doi.org/10.15419/bmrat.v4i08.228

Lawry J. Ovarian cancer: a patient centric approach. Middle East Medical Portal. 2018 [cited 2023 Sep 02].

Yan L, Shen J, Wang J, Yang X, Dong S, Lu S. Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose-Response. 2020;18(3):1559325820936161. doi:10.1177/1559325820936161 DOI: https://doi.org/10.1177/1559325820936161

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-96. doi:10.3322/caac.21456 DOI: https://doi.org/10.3322/caac.21456

Helder-Woolderink JM, Blok E, Vasen HF, Hollema H, Mourits M, De Bock G. Ovarian cancer in Lynch syndrome: a systematic review. Eur J Cancer. 2016;55:65-73. doi:10.1016/j.ejca.2015.12.005 DOI: https://doi.org/10.1016/j.ejca.2015.12.005

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9. doi:10.20892/j.issn.2095-3941.2016.0084 DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0084

Hatano Y, Hatano K, Tamada M, Morishige K-i, Tomita H, Yanai H, et al. A comprehensive review of ovarian serous carcinoma. Adv Anat Pathol. 2019;26(5):329. doi:10.1097/PAP.0000000000000243 DOI: https://doi.org/10.1097/PAP.0000000000000243

Lisio M-A, Fu L, Goyeneche A, Gao Z-h, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4):952. doi:10.3390/ijms20040952 DOI: https://doi.org/10.3390/ijms20040952

Watanabe T, Nanamiya H, Endo Y, Kojima M, Nomura S, Furukawa S, et al. Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer. J Ovar Res. 2021;14:1-9. doi:10.1186/s13048-021-00876-z DOI: https://doi.org/10.1186/s13048-021-00876-z

Bodelon C, Killian JK, Sampson JN, Anderson WF, Matsuno R, Brinton LA, et al. Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity. Clin Cancer Res. 2019;25(19):5937-46. doi:10.1158/1078-0432.CCR-18-3720 DOI: https://doi.org/10.1158/1078-0432.CCR-18-3720

Movahedi-Lankarani S, Baker PM, Gilks B, Soslow RA, Otis CN, Oliva E. Protocol for the examination of specimens from patients with carcinoma of the ovary. Northfield, IL: College of American Pathologists. 2012.

Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304. doi:10.3322/caac.21559 DOI: https://doi.org/10.3322/caac.21559

Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. 2019;11. doi:10.1177/1179299X19860815 DOI: https://doi.org/10.1177/1179299X19860815

Wang Q, Peng H, Qi X, Wu M, Zhao X. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther. 2020;5(1):137. doi:10.1038/s41392-020-0199-6 DOI: https://doi.org/10.1038/s41392-020-0199-6

Christie E, Bowtell D. Acquired chemotherapy resistance in ovarian cancer. Ann Oncol. 2017;28:VIII13-VIII15. doi:10.1093/annonc/mdx446 DOI: https://doi.org/10.1093/annonc/mdx446

Keyvani V, Riahi E, Yousefi M, Esmaeili S-A, Shafabakhsh R, Moradi Hasan-Abad A, et al. Gynecologic cancer, cancer stem cells, and possible targeted therapies. Front Pharmacol. 2022;13:823572. doi:10.3389/fphar.2022.823572 DOI: https://doi.org/10.3389/fphar.2022.823572

Anderson RK.

Hu Q, Kang W, Wu Q, Wang X, Wang Q, Luo T. Role of maintenance strategies in advanced epithelial ovarian cancer: a systematic review, network meta-analysis and cost-effectiveness analysis protocol. BMJ Open. 2021;11(12):e051037. doi:10.1136/bmjopen-2021-051037 DOI: https://doi.org/10.1136/bmjopen-2021-051037

Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer. 2020;30(7). doi:10.1136/ijgc-2020-001288 DOI: https://doi.org/10.1136/ijgc-2020-001288

Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137-54. doi:10.1158/2159-8290.CD-15-0714 DOI: https://doi.org/10.1158/2159-8290.CD-15-0714

Chandrasekaran A, Elias KM. Synthetic lethality in ovarian cancer. Mol Cancer Ther. 2021;20(11):2117-28. doi:10.1158/1535-7163.MCT-21-0500 DOI: https://doi.org/10.1158/1535-7163.MCT-21-0500

Giordo R, Wehbe Z, Paliogiannis P, Eid AH, Mangoni AA, Pintus G, et al. Nano-targeting vascular remodeling in cancer: recent developments and future directions. Semin Cancer Biol. 2022. doi:10.1016/j.semcancer.2022.03.001 DOI: https://doi.org/10.1016/j.semcancer.2022.03.001

Garrido MP, Fredes AN, Lobos-González L, Valenzuela-Valderrama M, Vera DB, Romero C. Current treatments and new possible complementary therapies for epithelial ovarian cancer. Biomedicines. 2021;10(1):77. doi:10.3390/biomedicines10010077 DOI: https://doi.org/10.3390/biomedicines10010077

Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. doi:10.1038/s41467-020-17670-y DOI: https://doi.org/10.1038/s41467-020-17670-y

Zhu J, Yan L, Wang Q. Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis. J Ovar Res. 2021;14(1):1-8. doi:10.1186/s13048-021-00862-5 DOI: https://doi.org/10.1186/s13048-021-00862-5

Pirš B, Škof E, Smrkolj V, Smrkolj Š. Overview of immune checkpoint inhibitors in gynecological cancer treatment. Cancers. 2022;14(3):631. doi:10.3390/cancers14030631 DOI: https://doi.org/10.3390/cancers14030631

Wanderley CWS, Correa TS, Scaranti M, Cunha FQ, Barroso-Sousa R. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications. Front Immunol. 2022;13:816642. doi:10.3389/fimmu.2022.816642 DOI: https://doi.org/10.3389/fimmu.2022.816642

Maiorano BA, Lorusso D, Maiorano MFP, Ciardiello D, Parrella P, Petracca A, et al. The interplay between PARP inhibitors and immunotherapy in ovarian cancer: the rationale behind a new combination therapy. Int J Mol Sci. 2022;23(7):3871. doi:10.3390/ijms23073871 DOI: https://doi.org/10.3390/ijms23073871

Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M-K, Hsu J-M, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711-20. doi:10.1158/1078-0432.CCR-16-3215 DOI: https://doi.org/10.1158/1078-0432.CCR-16-3215

Santhosh S, Nanjan M, Chandrasekar M. Ovarian solid tumors: current treatment and recent developments using stimuli-responsive polymers: a systemic review. J Drug Deliv Sci Technol. 2019;51:621-8. doi:10.1016/j.jddst.2019.03.018 DOI: https://doi.org/10.1016/j.jddst.2019.03.018

Yin W, Qian S-M. CD44v6-O-MWNTS-loaded gemcitabine and CXCR4 siRNA improves the anti-tumor effectiveness of ovarian cancer. Front Cell Develop Biol. 2021;9:687322. doi:10.3389/fcell.2021.687322 DOI: https://doi.org/10.3389/fcell.2021.687322

Giannini A, Di Dio C, Di Donato V, D’Oria O, Salerno MG, Capalbo G, et al. PARP inhibitors in newly diagnosed and recurrent ovarian cancer. Am J Clin Oncol. 2023;46(9):414-9. doi:10.1097/COC.0000000000001024 DOI: https://doi.org/10.1097/COC.0000000000001024

Article files

Additional Files

Received 2023-09-02
Accepted 2023-09-25
Published 2024-03-11

Publication details

Citation
Vol. 24 No. 2 (2024), pp. 230–237
Language
EN
License
CC BY 4.0
Section
Review

How to cite (Vancouver)

Abujamous L, Soltani A, Al-Thawadi H, Agouni A. Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer. Biomol Biomed. 2024;24(2):230–237. https://doi.org/10.17305/bb.2023.9757

Share

Related articles